Monograph

G04CA03 - Terazosin

Propably not porphyrinogenic

Rationale

No data pointing to CYP-interaction. Two references authorised / use with care.

Chemical description

Used in hypertrophic prostatic disease, 2-5 mg/d. Quinazoline derivative with selective effect on alpha-1-receptors in the bladder, giving rise to relaxation. Metabolized in the liver by hydrolysis and demethylation. No data pointing to CYP-interaction. South African list: use with care. French list: authorized

IPNet drug reports

Uneventful use reported in 3 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes G04C / G04CA or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames